Canada markets close in 4 hours 55 minutes

PureTech Health plc (PRTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
32.50+0.50 (+1.56%)
As of 11:04AM EST. Market open.

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333

Full Time Employees95

Key Executives

NameTitlePayExercisedYear Born
Ms. Daphne ZoharFounder, CEO & Exec. Director1.14MN/A1971
Dr. Bharatt M. Chowrira J.D., Ph.D.Pres, Sec., Chief Bus. Fin. & Operating Officer and Exec. Director909.15kN/A1965
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCDCo-Founder & Non-Exec. Director145kN/A1949
Dr. Bennett M. Shapiro M.D.Co-Founder & Board AdvisorN/AN/A1940
Dr. David R. Elmaleh Ph.D.Co-Founder & Sr. AdvisorN/AN/A1948
Dr. Joseph B. BolenChief Scientific OfficerN/AN/A1954
Ms. Allison Mead TalbotHead of Communications & Investor RelationsN/AN/AN/A
Mr. Spencer BallSr. VP of HRN/AN/AN/A
Dr. Eric Elenko Ph.D.Chief Innovation & Strategy OfficerN/AN/A1973
Ms. Aleksandra Filipovic M.D., Ph.D.Head of OncologyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of November 1, 2022 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.